AzTrials
AzTrials

Myocardial InfarctionMaraCat2NCT06000930

Cardiac Troponin Fragmentation After Heavy Physical Exercise The MaraCat2 Study

An observational study of Myocardial Infarction and Myocardial Injury, run by University of Turku at 1 site in Finland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Cardiac troponins are highly sensitive and specific biomarkers of cardiac injury and are in a key role in the diagnosis of acute myocardial infarction (MI). Minor troponin elevations are common after prolonged strenuous exercise without clinical symptoms of MI or myocardial injury. Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Myocardial Infarction, Myocardial Injury
What is being tested?
Troponin fragmentation
How many people
170 participants
Where
1 siteFinland
Study dates
19 Aug 2023to 1 Sep 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Marathon runners and patients with acute myocardial infarction as a control group

Who may be able to join

  • participating marathon race or treated for Type 1 myocardial infarction and giving informed consent

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

Finland1 site
  • University of Turku

    Turku, 20300

Other trials in Finland

About this study

Cardiac troponins are highly sensitive and specific biomarkers of cardiac injury and are in a key role in the diagnosis of acute myocardial infarction (MI). Minor troponin elevations are common after prolonged strenuous exercise without clinical symptoms of MI or myocardial injury. Importantly, currently used high-sensitivity troponin T (cTnT) test detects also smaller troponin fragments which may cause troponin elevation after exercise and lead to false diagnosis of MI.

In the present study protocol, we compare the characteristics troponin release after marathon race and Type 1 MI with the improved version of our novel troponin fragmentation test (SuperTropo test) and the commercial cTnT test.

Read more

A total of 65 recreational runners participating in the 2023 Paavo Nurmi Marathon in Turku are recruited. All participants give a blood sample during the post-race visit (within 30 min after finishing the marathon).

A control group of 90 patients with acute Type 1 MI are recruited among patients admitted to Heart Centre of Turku University Hospital.

Commercial cTnT and long troponin component of cTnT analyzed witha novel immunoassay are dtermined in all subjects to assess cTnT fragmentation. TYhe main aims of the study are:

To assess how often cTnT is elevated after marathon running and which factors affect the cTnT rise? Is the fragmentation of troponin more common after marathon race compared with Type 1 MI and can the novel Supertropo test separate execise-induced troponin rise from those caused by MI ?

Read the detailed description

Cardiac troponins are highly sensitive and specific biomarkers of cardiac injury and are in a key role in the diagnosis of acute myocardial infarction (MI). Minor troponin elevations are common after prolonged strenuous exercise without clinical symptoms of MI or myocardial injury.

Based on a small gel filtration chromatography study the released troponin in this condition seems to be predominantly in the form of small fragments. These smaller cytosolic troponin fragments may more easily traverse across cell membranes that have become leaky but not irreversibly damaged. Importantly, currently used high-sensitivity troponin T (cTnT) test detects also smaller troponin fragments which may lead to false diagnosis of MI.

In a Proof-of-Principle study we developed a novel immunoassay which is much simpler and more sensitive than previously used laboratory methods for studying cTnT fragmentation. In the present study protocol, we compare the characteristics troponin release after marathon race and Type 1 MI with the improved version of our novel troponin fragmentation test (SuperTropo test) and the commercial cTnT test.

A total of 65 recreational runners participating in the 2023 Paavo Nurmi Marathon in Turku are recruited to the MaraCat2 Study with an open email invitation. All participants give a blood sample during the post-race visit (within 60 min after finishing the marathon).

A control group of 90 patients with acute Type 1 MI are recruited among patients admitted to Heart Centre of Turku University Hospital. Coronary angiography is performed in all included patients to confirm culprit lesion and the MI diagnosis. All included patients are treated with primary or urgent percutaneous coronary intervention. Only patients with <24 delay from symptom onset to blood sample are included to avoid the effects of later gradual fragmentation of cTnT in the circulation.

Certified laboratory services by Turku University Hospital (TYKSLAB) take care of blood samples. After centrifugation, serum is aliquoted, frozen and stored at -70 °C for later analysis. Analysis is performed on a single day using the same calibration and set-up to minimize variation.

cTnT was analyzed using a commercial high-sensitive assay (Roche Diagnostics GmbH, Mannheim, Germany).

A novel sensitive time-resolved immunofluorometric assay is used for the detection of long cTnT forms (long cTnT). The long cTnT assay follows the sandwich type immunoassay format and utilizes time-resolved-fluorescence (TRF) as the measurement platform.

The main aims of the study are:

To assess how often cTnT is elevated after marathon running and which factors affect the cTnT rise? Is the fragmentation of troponin complex (assessed by long cTnT/ total cTnT ratio) more common after marathon race compared with Type 1 MI? Is the novel Supertropo test able to separate exercise-induced troponin elevations from those caused by MI ? All participants provide written informed consent. The study complies with Declaration of Helsinki as revised in 2002 and the study protocol was approved by the Medical Ethics Committee of the Hospital District of Southwest Finland.

Statistical analysis Continuous variables are reported as mean ± standard deviation when normally distributed, and as median [inter-quartile range (IQR)] if they were skewed unless stated otherwise. The normality of the data distribution is examined by the Shapiro-Wilk test. Statistical significance was assumed at a p value < 0.05. Categorical variables were described with absolute and relative (percentage) frequencies. Chi-squared test and Fisher's exact test are used for categorical variables as appropriate. Independent samples t-test and Mann-Whitney U test are used for univariate analysis. Correlation between continuous variables are estimated using the Spearman test. Linear regression analysis with backward selection is used to identify factors significantly relating to post-race cTnT levels. All predictors with a P value < 0.1 in univariate analysis were included in the final regression model.

Being tested
Troponin fragmentation
Keywords
exercise, troponin, myocardial infarction, myocardial injury
Medical subject headings
Myocardial Infarction, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Troponin fragmentationDiagnostic test

    laboratory test from blood sample

Study groups in NCT06000930
Study groupRoleWhat they receive
marathon runnersMarathon runners
Receives: Diagnostic Test: Troponin fragmentation
myocardial infarctionPatients with Type 1 myocardial infarction
Receives: Diagnostic Test: Troponin fragmentation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Magnitude of Troponin fragmentation in the post-race and post-MI (<24h) blood samples

    Ratio of long troponin component to total troponin T in the post-race and post-MI (<24h) blood sample

    Measured: < 1 hour after marathon race and < 24 hours after myocardial infarction

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2023
  2. Study start19 Aug 2023
  3. Primary completion1 Sep 2024 (estimated)
  4. Study completion1 Sep 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
170 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06000930
Sponsor's protocol ID
13.06.2023/207
Acronym
MaraCat2
Status last verified
May 2024
First submitted
13 Aug 2023
Last updated
8 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Airaksinen KEJ, Paana T, Vasankari T, Salonen S, Tuominen T, Linko-Parvinen A, Pallari HM, Hellman T, Teppo K, Heinonen OJ, Jaakkola S, Wittfooth S. Composition of cardiac troponin release differs after marathon running and myocardial infarction. Open Heart. 2024 Nov 17;11(2):e002954. doi: 10.1136/openhrt-2024-002954.

    PubMed 39551608

Questions about this trial

What is this clinical trial studying?

An observational study of Myocardial Infarction and Myocardial Injury, run by University of Turku at 1 site in Finland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Magnitude of Troponin fragmentation in the post-race and post-MI (<24h) blood samples (time frame: < 1 hour after marathon race and < 24 hours after myocardial infarction). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06000930, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in